SteelPeak Wealth LLC Grows Position in Edwards Lifesciences Co. (NYSE:EW)

SteelPeak Wealth LLC lifted its holdings in Edwards Lifesciences Co. (NYSE:EWFree Report) by 7.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,934 shares of the medical research company’s stock after buying an additional 199 shares during the period. SteelPeak Wealth LLC’s holdings in Edwards Lifesciences were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Edwards Lifesciences by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after buying an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Edwards Lifesciences by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after purchasing an additional 1,644,869 shares during the period. Brown Advisory Inc. increased its position in shares of Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares during the last quarter. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 2.4% in the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after buying an additional 393,109 shares during the period. Finally, Norges Bank acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $648,540,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 5,625 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $90.45, for a total value of $508,781.25. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,764,242.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $4,108,777.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 5,625 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $90.45, for a total transaction of $508,781.25. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,764,242.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,242 shares of company stock worth $2,498,870. 1.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Barclays lowered their price target on Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Piper Sandler reduced their price target on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Wells Fargo & Company reduced their target price on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a report on Thursday, July 25th. Finally, Canaccord Genuity Group reduced their price objective on shares of Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a report on Thursday, July 25th. Fourteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $82.10.

Get Our Latest Analysis on EW

Edwards Lifesciences Trading Up 0.3 %

Shares of Edwards Lifesciences stock traded up $0.20 during trading hours on Friday, reaching $68.32. 324,031 shares of the company’s stock were exchanged, compared to its average volume of 4,034,742. The firm has a market capitalization of $41.17 billion, a price-to-earnings ratio of 29.37, a price-to-earnings-growth ratio of 2.57 and a beta of 1.11. The company has a fifty day moving average of $81.15 and a 200-day moving average of $85.80. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. Edwards Lifesciences’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.66 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.